

Tae Seop Lim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4587624/publications.pdf>

Version: 2024-02-01

20
papers

298
citations

1162889

8
h-index

887953

17
g-index

23
all docs

23
docs citations

23
times ranked

653
citing authors

#	ARTICLE	IF	CITATIONS
1	Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 344-353.	0.6	68
2	Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma. <i>Investigational New Drugs</i> , 2019, 37, 567-572.	1.2	44
3	Therapeutic Strategies for Well-differentiated Papillary Mesothelioma of the Peritoneum. <i>Japanese Journal of Clinical Oncology</i> , 2013, 43, 996-1003.	0.6	27
4	Use of the Delta Neutrophil Index as a Prognostic Factor of Mortality in Patients with Spontaneous Bacterial Peritonitis: Implications of a Simple and Useful Marker. <i>PLoS ONE</i> , 2014, 9, e86884.	1.1	25
5	Sarcopenia Is Independently Associated with the Degree of Liver Fibrosis in Patients with Type 2 Diabetes Mellitus. <i>Gut and Liver</i> , 2020, 14, 626-635.	1.4	19
6	Alpha-Fetoprotein, Des-Gamma-Carboxy Prothrombin, and Modified RECIST Response as Predictors of Survival after Transarterial Radioembolization for Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2019, 30, 1194-1200.e1.	0.2	15
7	An observational study on long-term renal outcome in patients with chronic hepatitis B treated with tenofovir disoproxil fumarate. <i>Journal of Viral Hepatitis</i> , 2020, 27, 316-322.	1.0	13
8	Is liver biopsy still useful in the era of non-invasive tests?. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 302-304.	4.5	11
9	Predictors of Discordance in the Assessment of Skeletal Muscle Mass between Computed Tomography and Bioimpedance Analysis. <i>Journal of Clinical Medicine</i> , 2019, 8, 322.	1.0	9
10	Transarterial Chemoembolization in Treatment-Naïve and Recurrent Hepatocellular Carcinoma: A Propensity-Matched Outcome Analysis. <i>Digestive Diseases and Sciences</i> , 2019, 64, 3660-3668.	1.1	8
11	Conditional Survival Estimates Improve Over Time for Patients with Hepatocellular Carcinoma: An Analysis for Nationwide Korea Cancer Registry Database. <i>Cancer Research and Treatment</i> , 2019, 51, 1347-1356.	1.3	8
12	Refractoriness to transarterial chemoembolization in patients with recurrent hepatocellular carcinoma after curative resection. <i>PLoS ONE</i> , 2019, 14, e0214613.	1.1	7
13	Predictive score for hepatocellular carcinoma after hepatitis B e antigen loss in patients treated with entecavir or tenofovir. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1052-1060.	1.0	7
14	Diagnostic Performance of Serum Asialo- α 1-acid Glycoprotein for Advanced Liver Fibrosis or Cirrhosis in Patients with Chronic Hepatitis B or Nonalcoholic Fatty Liver Disease. <i>Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The</i> , 2019, 74, 341.	0.2	6
15	Use of sofosbuvir in chronic kidney disease: Is it necessary?. <i>Clinical and Molecular Hepatology</i> , 2017, 23, 308-310.	4.5	6
16	Novel Liver Stiffness-Based Nomogram for Predicting Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis B Virus Infection Initiating Antiviral Therapy. <i>Cancers</i> , 2021, 13, 5892.	1.7	6
17	Non-O1, Non-O139 <i>Vibrio cholerae</i> Septicemia after Acupuncture. <i>The Ewha Medical Journal</i> , 2013, 36, S22.	0.1	5
18	Risk assessment of hepatocellular carcinoma and liver-related events using ultrasonography and transient elastography in patients with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1362-1372.	1.0	4

#	ARTICLE	IF	CITATIONS
19	Establishment and validation of a risk prediction model in patients with hepatocellular carcinoma treated with transarterial radioembolization. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 739-747.	0.8	2
20	External Validation of the FSAC Model Using On-Therapy Changes in Noninvasive Fibrosis Markers in Patients with Chronic Hepatitis B: A Multicenter Study. <i>Cancers</i> , 2022, 14, 711.	1.7	1